# China NMPA Drug Inspection - Anhui Taiyuan Traditional Chinese Medicine Pieces Co., Ltd. - mastic

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-taiyuan-traditional-chinese-medicine-pieces-co-ltd/3fd60c44-c340-4134-9dfc-86434d17677b/
Source feed: China

> China NMPA drug inspection for Anhui Taiyuan Traditional Chinese Medicine Pieces Co., Ltd. published January 12, 2017. Drug: mastic. The Tibet Autonomous Region Food and Drug Inspection Institute, operating under the regulatory framework of China's Stat

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement of Substandard Drugs Found in the 2016 Spot Check in Tibet Autonomous Region
- Company Name: Anhui Taiyuan Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2017-01-12
- Drug Name: mastic
- Inspection Finding: Quenching spots are substandard; counterfeit product.
- Action Taken: The product was substandard and was identified as a counterfeit product.
- Summary: The Tibet Autonomous Region Food and Drug Inspection Institute, operating under the regulatory framework of China's State Food and Drug Administration (SFDA), announced the results of non-compliant drug sampling inspections conducted in 2016, with the findings released on January 12, 2017. These inspections identified multiple drug products failing to meet established quality standards.Key violations included: Qiqihar Xianhe Traditional Chinese Medicine Decoction Pieces Processing Plant, Heilongjiang Province, had their Typha Pollen (Decoction Pieces) found with non-compliant total ash levels and classified as a counterfeit product. An Agarwood product, sourced from Shannan Everest Clinic and originating from Guangdong, exhibited an unqualified appearance. A Frankincense product from Shannan Yumbulagang Tibetan Medicine Factory, originating from India, also presented an unqualified appearance. Lastly, Anhui Yaozhiyuan Traditional Chinese Medicine Pieces Co., Ltd.'s Frankincense product, sampled from Lhasa Sunshine Urology and Reproductive Hospital, displayed unqualified quenching spots and was likewise categorized as counterfeit. The inspections were based on supplementary testing methods and items approved by the SFDA. The identification of counterfeit products and significant quality issues underscores the critical need for manufacturers and distributors to adhere strictly to regulatory standards, necessitating immediate corrective actions and further regulatory scrutiny to ensure public safety and product integrity.

Company: https://www.globalkeysolutions.net/companies/anhui-taiyuan-traditional-chinese-medicine-pieces-co-ltd/2391fa22-687e-48e5-8e7e-c896278012ad/